AnPac Bio Files Coronavirus Detection Patent and Initiates Related Research Project
While AnPac Bio's focus has been on cancer risk assessment, AnPac Bio's bio-physical-property based CDA technology has also been evaluated for other major non-cancerous diseases, and valuable information and data have been collected on clinical samples on major non-cancerous diseases. "Exploring the CDA technology's ability to detect the risk of major non-cancerous diseases and broadening its product offerings for other life threatening diseases has been part of AnPac Bio's business strategies for years," commented Chairman and CEO Dr.
About AnPac Bio
AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 121 issued patents as of
For more information, please visit: https://www.Anpacbio.com.
For investor and media inquiries, please contact:
Phone: +1-267-810-6776 (US)
Ascent Investor Relations LLC
Phone: +1-917-609-0333 (US)
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company's future financial and operating performance. The Company has attempted to identify forward-looking statements by terminologies including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "target," "aim," "predict," "outlook," "seek," "goal" "objective," "assume," "contemplate," "continue," "positioned," "forecast," "likely," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from those expressed or implied by any forward-looking statement. Known and unknown risks, uncertainties and other factors include, but are not limited to, the implementation of our business model and growth strategies; trends and competition in the cancer screening and detection market; our expectations regarding demand for and market acceptance of our cancer screening and detection tests and our ability to expand our customer base; our ability to obtain and maintain intellectual property protections for our CDA technology and our continued research and development to keep pace with technology developments; our ability to obtain and maintain regulatory approvals from the NMPA, the FDA and the relevant
View original content to download multimedia:http://www.prnewswire.com/news-releases/anpac-bio-files-coronavirus-detection-patent-and-initiates-related-research-project-301012487.html